HOME >> MEDICINE >> NEWS
Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration

NEW ORLEANS, October 21, 2004 -- Eyetech Pharmaceuticals, Inc. (Nasdaq: EYET) today announced that the treatment effect with the investigational drug Macugen (pegaptanib sodium injection) extends for two years in patients with neovascular or wet, age-related macular degeneration (AMD), who are at risk of losing their vision. A treatment benefit was also seen for patients who received Macugen for two years compared to those only receiving one year of therapy.

The data confirm that patients benefit from two years of treatment with Macugen for wet AMD. The second year data for Macugen will be presented by Anthony P. Adamis, M.D., Chief Scientific Officer, Eyetech Pharmaceuticals and Steven Schwartz, M.D., Chief, Retina Division, Jules Stein Eye Institute, University of California, Los Angeles, at the Retina Subspecialty symposium of the American Academy of Ophthalmology Meeting on Friday, October 22, 2004 at 8:00 a.m. Central Time and 10:38 a.m. Central Time respectively.

Eyetech and Pfizer are partnering to develop and market Macugen, a treatment for neovascular or wet AMD, the leading cause of severe vision loss in patients older than 50 years of age in the developed world. Eyetech and Pfizer have filed an NDA for Macugen for neovascular AMD with the FDA. Macugen has been assigned priority review status and the PDUFA date is December 17, 2004.

"We are excited about the new data because they confirm that treatment with Macugen is effective in patients with neovascular AMD who are at risk of losing their vision," said David R. Guyer, M.D., Chief Executive Officer, Eyetech Pharmaceuticals. "The two year data on Macugen demonstrate that longer term use may be beneficial for patients suffering from this chronic disease."

These data are from two, pivotal Phase II/III randomized, multi-center, double-masked studies in patients with all subtypes of neovascular AMD. 1,186 patients were initially randomized to receive one
'"/>


21-Oct-2004


Page: 1 2 3

Related medicine news :

1. The Gerontological Society of America announces Hartford Fellowship recipients
2. TB Alliance announces new drug discovery program with GlaxoSmithKline
3. ASGE announces grant recipients in annual research awards program
4. Novartis announces collaboration with Bayer for EMSELEX
5. American College of Chest Physicians announces new Critical Care Institute
6. Department of Energy announces new agreement with USC, national labs and private company
7. ACP announces international medical fellowship
8. St. Jude Medical announces CRT patients showed improvement in the RHYTHM ICD study
9. St. Jude Medical announces PAVE and DINAMIT clinical trial results
10. National Inventors Hall of Fame announces 2004 class of inventors
11. Joslin announces first international affiliate in Bahrain

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/4/2020)... ... June 04, 2020 , ... The experience of making or watching a film ... art. Then came the COVID-19 pandemic and physical distancing. “The German film industry came ... Film Festival (BIFF). That is, “all stages of the film business, exhibition, production, financing ...
(Date:6/2/2020)... ... June 02, 2020 , ... Catalent, ... drugs, biologics, cell and gene therapies, and consumer health products, today announced the ... succeeds John McGill, who, following a period of transition, plans to retire in ...
(Date:5/30/2020)... PALO ALTO, Calif. (PRWEB) , ... May 30, ... ... helping them with advanced technology and virtual solutions that can meet the needs ... post-pandemic world. , HashCash’s healthcare solutions abide by the necessary compliances ...
(Date:5/27/2020)... ... May 27, 2020 , ... Productive Plastics, a leading ... face shields to be used as personal protective equipment (PPE) to combat ... single use, made to be worn by frontline healthcare professionals and for any ...
(Date:5/26/2020)... ... May 26, 2020 , ... New research ... the brain causing post infectious encephalitis. The work was conducted to determine ... (Pediatric Acute-onset Neuropsychiatric Syndrome) could adversely attack the central nervous system and ...
Breaking Medicine News(10 mins):
(Date:6/3/2020)... , ... June 03, 2020 , ... ... over 75, announced today the addition of connected device capabilities to its mobile ... providers. The expanded capabilities come at a time when an increasing number of ...
(Date:6/2/2020)... TAMPA, Fla. (PRWEB) , ... June 02, 2020 ... ... non-clinical healthcare, Harmony Healthcare announced today that in response to COVID-19 it is ... job security, updated remote and on-site solutions, reimbursements, and a host of digital ...
(Date:5/30/2020)... ... May 29, 2020 , ... ... return-to-work mobile and web based solution People1 Care to help organizations ... companies transition into the 'new normal’ through daily wellness screenings, social distancing support, ...
Breaking Medicine Technology:
Cached News: